Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Active surveillance for localized prostate cancer: An analysis of patient contacts and utilization of healthcare resources

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Robotic versus laparoscopic urological surgery: incidence of reoperation and complications

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Implantation of the argus sling in a hard-to-treat patient group with urinary stress incontinence

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Abstract Objective. Evidence supports active surveillance (AS) as a means to reduce overtreatment of low-risk prostate cancer (PCa). The consequences of close and long-standing follow-up with regard to outpatient visits, tests and repeated biopsies are widely unknown. This study investigated the trajectory and costs of AS in patients with localized PCa. Materials and methods. In total, 317 PCa patients were followed in a prospective, single-arm AS cohort. The primary outcomes were number of patient contacts, prostate-specific antigen (PSA) tests, biopsies, hospital admissions due to biopsy complications and patients eventually undergoing curative treatment. The secondary outcome was cost. Results. The 5 year cumulative incidence of discontinued AS in a competing-risk model was 40%. During the first 5 years of AS patients underwent a median of two biopsy sets, and patients were seen in an outpatient clinic including PSA testing three to four times annually. In total, 38 of the 406 biopsy sessions led to hospital admission and 87 of the 317 patients required treatment for bladder outlet obstruction (BOO). With a median of 3.7 years' follow-up, the total cost of AS was euro (€) 1,240,286. Assuming all patients had otherwise undergone primary radical prostatectomy, the cost difference favoured AS with a net benefit of €662,661 (35% reduction). Conclusions. AS entails a close clinical follow-up with a considerable risk of rebiopsy complication, treatment of BOO and subsequent delayed definitive therapy. This risk should be weighed against a potential economic benefit and reduction in the risk of overtreatment compared to immediate radical treatment.

Original languageEnglish
JournalScandinavian Journal of Urology and Nephrology
Volume49
Issue number1
Pages (from-to)43-50
Number of pages8
ISSN0036-5599
DOIs
Publication statusPublished - Feb 2015

ID: 44854110